View in EDS

Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.

Saved in:
Bibliographic Details
Title: Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.
Authors: Scheid JF; Merck & Co., Inc., Rahway, NJ, United States., Cunningham-Bussel K; Merck & Co., Inc., Rahway, NJ, United States., Kim N; Merck & Co., Inc., Rahway, NJ, United States., Agarwal S; Merck & Co., Inc., Rahway, NJ, United States., Nieddu G; Merck & Co., Inc., Rahway, NJ, United States., Cote J; Merck & Co., Inc., Rahway, NJ, United States., Lemoine L; Merck & Co., Inc., Rahway, NJ, United States., Decaesteker T; Merck & Co., Inc., Rahway, NJ, United States., Mendez L; Merck & Co., Inc., Rahway, NJ, United States., Paul E; Merck & Co., Inc., Rahway, NJ, United States., Love-Gregory L; Merck & Co., Inc., Rahway, NJ, United States., Contreras AV; Merck & Co., Inc., Rahway, NJ, United States., Zhao X; Merck & Co., Inc., Rahway, NJ, United States., Franco-Dilone L; Merck & Co., Inc., Rahway, NJ, United States., Pang L; Merck & Co., Inc., Rahway, NJ, United States., Baltus GA; Merck & Co., Inc., Rahway, NJ, United States., Beaumont M; Merck & Co., Inc., Rahway, NJ, United States., Shah K; Merck & Co., Inc., Rahway, NJ, United States., Higginson-Scott N; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States., Kis-Toth K; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States., Otipoby KL; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States., Viney JL; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States., Sicard E; Altasciences, Montreal, QC, Canada., Rottey S; Universiteit Gent, Gent, Belgium., Sundy JS; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States., Van Dyck K; Merck & Co., Inc., Rahway, NJ, United States., Laethem T; Merck & Co., Inc., Rahway, NJ, United States., Larson P; Merck & Co., Inc., Rahway, NJ, United States., Sutradhar S; Merck & Co., Inc., Rahway, NJ, United States., Wnek R; Merck & Co., Inc., Rahway, NJ, United States., Bueters T; Merck & Co., Inc., Rahway, NJ, United States., Lai E; Merck & Co., Inc., Rahway, NJ, United States., Stoch SA; Merck & Co., Inc., Rahway, NJ, United States., Iwamoto M; Merck & Co., Inc., Rahway, NJ, United States., Robbins JA; Merck & Co., Inc., Rahway, NJ, United States.
Source: ImmunoHorizons [Immunohorizons] 2025 Mar 26; Vol. 9 (5).
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101708159 Publication Model: Print Cited Medium: Internet ISSN: 2573-7732 (Electronic) Linking ISSN: 25737732 NLM ISO Abbreviation: Immunohorizons Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2573-7732
DOI:10.1093/immhor/vlaf005